Vallon Pharmaceuticals, Inc. announced the formation of and initial appointments to its Scientific Advisory Board (SAB). The SAB will guide and advise the Company as it advances its novel abuse-deterrent platform technology and its lead development programs ADAIR and ADMIR, which leverage the technology to resist manipulation for snorting and provide barriers to injection. Dr. Stephen V. Faraone, Dr. Jeffrey Newcorn and Dr. Anthony Rostain each bring distinct expertise and invaluable leadership in the psychiatry field as a whole, but more specifically in ADHD, which will be an important asset to the Company. Stephen V. Faraone, PhD, is Distinguished Professor, Departments of Psychiatry and Neuroscience & Physiology, SUNY Upstate Medical University. Dr. Faraone also currently serves as the Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Jeffrey Newcorn, MD, is Professor of Psychiatry and Pediatrics and Director of the Division of ADHD and Learning Disorders; Icahn School of Medicine at Mount Sinai. He was a founding member of the board of directors of the American Professional Society for ADHD and Related Disorders (APSARD), and has served as President since 2020. Anthony Rostain, MD, is Chief of Psychiatry and Behavioral Health at Cooper University Healthcare,Chair and Professor of Psychiatry and Pediatrics at Cooper Medical School of Rowan University and is Emeritus Professor of Psychiatry and Pediatrics at the University of Pennsylvania Perelman School of Medicine.